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SUMMARY 
 
 
Background: Epilepsy is refractory to medical treatment in about one-third of the patients. 
The exact pathological mechanism of epilepsy pharmacoresistance is still unclear, but a 
decreased antiepileptic drug (AED) uptake into the brain is suspected to play a role.  P-
glycoprotein (Pgp), a transmembrane transporter encoded by ABCB1 gene and located at the 
endothelial cells of the blood-brain barrier (BBB), has been associated with epilepsy 
pharmacoresistance. 
Objective:  To analyze the effect of two ABCB1 gene polymorphisms, C3435T and 
G2677T/A, on phenobarbital (PB) concentrations in the cerebrospinal fluid (CSF) and  
 serum (S) and to assess the relationship of ABCB1 polymorphisms to phenobarbital 
penetration across BBB in vivo and seizure frequency. 
Methods: CSF PB and S PB concentrations were measured in 60 patients with idiopathic 
primary generalized epilepsy receiving phenobarbital monotherapy. CSF/S PB concentration 
ratio was calculated as an index of phenobarbital penetration across BBB. The patients were 
genotyped for the ABCB1 gene C3435T and G2677T/A polymorphisms. Seizure frequency 
was recorded during the 6-month phenobarbital monotherapy. 
Results: Patients with different C3435T polymorphism had significantly different CSF PB 
concentrations and CSF/S PB concentration ratio. In comparison with CT heterozygotes and 
TT homozygotes, CC homozygotes had a significantly lower CSF PB concentration 
(p=0.006) and CSF/S PB concentration ratio (p<0.001).  G2677T/A polymorphism showed no 
such effect (p=0.466).  CC genotype and low CSF/S PB concentration ratio correlated with 
increased seizure frequency.  
Conclusions: C3435T polymorphism of ABCB1 gene was demonstrated in vivo to 
significantly influence the CSF/S PB concentration  ratio and seizure frequency.  
  
 
 
 
INTRODUCTION 
 
Epilepsy is one of the most frequent neurologic disorders, affecting approximately 1-2% of 
the world population.1,2  In around 20-30% of the patients, the condition is refractory to 
medical treatment. 3-8 Clinically, epilepsy is considered pharmacoresistant if seizures continue 
to occur even though the patient is treated with two to three first-line antiepileptic drugs 
(AEDs) usually used for the treatment of given epilepsy.9-14 Characterised by high morbidity 
and mortality, pharmacoresistant forms of epilepsy remain a major health problem despite 
advances in antiepileptic pharmacotherapy and new AEDs developed in the last two 
decades.1,2,15 
Most patients who are resistant to one major AED are also refractory to other AEDs, although 
the drugs act by different mechanisms.5,15  The real pathological mechanism of drug 
resistance remains obscure in spite of numerous studies conducted. 10-14  Neither the reported 
associations of pharmacoresistance with early onset of the disease, multiple seizure types, 
high frequency of seizures before treatment, a history of febrile seizures, structural brain 
lesions, and malformations of cortical development have illuminated the mechanism of this 
phenomenon. 10-14, 16-18  Furthermore, drug resistance is not associated with the same type of 
epilepsy. The same type of the disorder may be drug resistant in one patient and drug 
responsive in another.19 The fact that most patients with refractory epilepsy are resistant to 
most AEDs, although the drugs act by different mechanisms, points to a nonspecific 
mechanism such as decreased drug uptake into the brain as a major cause of 
pharmacoresistance.5,15,7,8,20,21 
 During the last 12 years, reports on P-glycoprotein 750 (Pgp) involvement in epilepsy 
pharmacoresistance have appeared in the literature.4,6-9,14,15 Pgp is a large transmembrane 
protein expressed in endothelial cells of the blood-brain barrier (BBB), and functions as a 
drug-transport pump transporting a variety of drugs from the brain back into the blood and 
reducing drug accumulation in the brain. 22-28 Accumulated research evidence from animal 
and in vitro studies suggests that some AEDs are Pgp substrates.9,13,15,21,29-34  Pgp is encoded 
by ABCB1 gene and its expression and function are associated with the ABCB1 C3435T 
polymorphism.6,8,15,35 Based on these data, some authors report on a possible conection 
between the C3435T polymorphism of ABCB1 gene and pharmacoresistance in epilepsy 
patients. 19,36,37 On the other hand, there are studies in which no association was found 
between the C3435T polymorphism of ABCB1 gene and Pgp expression and the 
pharmacoresistance of epilepsies.38,39  
So far, there has been no conclusive evidence that the altered Pgp function is associated with 
pharmacoresistance. No in vivo human studies have been performed to investigate if C3435T 
mutation of ABCB1 gene influences the brain uptake of AEDs, which is one of the basic 
presumptions of the mechanism of pharmacoresistance.  
The aim of this study was to investigate the relationship between C3435T and G2677T/A 
polymorphisms of ABCB1 gene and the brain uptake of phenobarbital (PB) in patients with 
primary generalized epilepsy. 
  
METHODS 
 
Genotyping was performed in 60 unrelated patients (35 male and 25 woman; mean age 37±9 
years) who suffered from idiopathic primarily generalized epilepsy (PGE) with tonic-clonic 
seizures. All patients were diagnosed with PGE on the basis of  anamnesis, heteroanamnesis 
and video-electroencephalographic recording. Symptomatic epilepsy was excluded by 
magnetic resonance imaging (MRI) at 1.5 or 2 T. The patients were randomly selected from 
the database of the Reference Center for Epilepsy of the Ministry of Health and Social 
Welfare of Croatia at the Zagreb University Hospital Center. All patients recieved 
phenobarbital for 6 months and did not take any other AED or other drugs known to be a Pgp 
substrate. They were also asked to keep records on the number of seizures during the 6-month 
period of phenobarbital monotherapy. After at least 3 months of phenobarbital monotherapy, 
the patients undervent lumbar puncture. Cerebrospinal fluid (CSF) and serum (S) sampling 
was performed at the same time, at 8.00 a.m., before the morning dose of phenobarbital.  PB 
concentration was measured in both CSF (CSF PB) and serum (S PB) by fluorescence 
polarization immunoassay (FPIA) on TDx analyzers (Abbott Laboratories, Abbott Park, IL, 
USA).40 The CSF/S PB concentration ratio was calculated as an  index of phenobarbital 
crossing the blood-brain brrier.  
All patients were genotyped for the C3435T (CC,CT and TT genotypes) and G2677T/A  
(GG,GT and TT genotypes) polymorphisms of ABCB1 gene. Five mililiters of blood with 
Na-EDTA was collected for genotyping procedure. Genomic DNA was extracted from 
peripheral lymphocytes using salting out procedure.41 Analysis of 2677 G/T/A 
polymorphisms in exon 21 was performed according to the method described by Cascorbi et 
al,42, whereas 3435C/T polymorphism in exon 26 was analyzed by the method described by 
Sakaeda et al.43. Substitution G2677T/A in exon 21 was detected by  polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) method with Ndell 
restriction endonuclease. The G and T alleles were represented by 193 bp and 144 bp 
fragments, respectively.  PCR-RFLP method with Banl restriction endonuclease was used to 
detect MDR1-C3435T substitution. The C and T alleles were represented by 198 bp and 224 
bp fragments, respectively.  
The study was approved by the local ethics committee and all patients gave a written 
informed consent before entering the study.  
Data were presented as mean values ± standard deviation (S.D.) Since the C3445T genotypes 
did not follow a Gaussian distribution, Kruskal-Wallis test was used to compare C3435T 
genotype groups for phenobarbital concentration in the cerebrospinal fluid and serum and 
CSF/S  PB concentration ratio. G2677T/A genotype groups were compared for the same 
parameters using Kruskal-Wallis test. The relationship between CSF/S PB concentration ratio 
and seizure frequency over the 6-month period was analyzed by ANOVA-MANOVA one-
way test followed by a Tukey test. Statistical analysis was performed with SPSS 10.0 for 
Windows (SPSS Inc., Chicago, IL,USA), and  the level of significance was set at p≤0.05.  
 
 
 
 
RESULTS 
 
 We found the differences in both CSF PB concentration and CSF/S PB concentration ratio 
among patients with different C3435T genotypes (Table 1). The S PB concentration did not 
differ among patients with CC, CT or TT genotype, but the penetration of PB into the brain 
was reduced in CC homozygotes, who had a significantly lower relative concentration of PB 
in CSF than did CT heterozygotes and TT homozygotes . 
 
Table 1. Influence of C3435T polymorphism on CSF/S PB  
 
Kruskal-Wallis p=0.0001; H=18.52738 
 
Table 1 Phenobarbital (PB) concentration in cerebrospinal fluid (CSF) and serum (S) and CSF/S PB 
ratio with respect to C3435T genotype of 60 patients with primary generalized epilepsy 
C3435T polymorphism (mean+SD) Parameter 
CC (n=16) CT (n=31) TT (n=13) 
Pa 
PB doses/mg 
(range) 
550.0±81.7 
(400-700) 
532.3±116.6 
(200-800) 
530.8±125.1 
(300-800) 
0.836 
PB S (µmol/L) 102.2±15.0 102.9±25.3 103.8±13.6 0.947 
PB CSF (µmol/L) 44.1±12.9 52.5±13.5 64.4±14.4 0.006 
CSF/S PB 0.4±0.1 0.5±0.1 0.6±0.1 <0.001 
aKruskal-Wallis test, H=18.52738. 
 
 
In the same patients, no differences in CSF PB concentration and CSF/S PB concentration 
ratio were found with respect to the G2677T/A genotype (Table 2). Not a single variant A 
allele was detected in our patients, and age and sex did not correlate with differences in 
CSF/S PB ratio (data not shown).  
 
Table 2. Influence G2677T/A polymorphism on CSF/S PB 
 
Kruskal-Wallis p=0.466; H=1.527117 
 
Table 2 Phenobarbital (PB) concentration in cerebrospinal fluid (CSF) and serum (S) and CSF/S PB 
ratio with respect to G2677T/A genotype of 60 patients with primary generalized epilepsy 
Parameter polymorphism (mean+SD) Pa 
GG (n=14) GT (n=29) TT (n=17) 
PB doses/mg 
(range) 
521±152..8 548.3±82.8 529.4±84.89 0.535 
PB S (µmol/L) 104.03±11.32 102.7±25.73 102.36±16.96 0.8274 
PB CSF (µmol/L) 50.75±14.06 53.38±13.45 53.69±18.87 0.4323 
CSF/S PB 0.49±0.11 0.53±0.11 0.52±0.14 0.466 
aKruskal-Wallis test; H=1.527117. 
 
Seizure frequency correlated with CSF/S PB concentration ratio (Table 3). Patients with 
lower CSF/S PB concentration ratio had a higher incidence of seizures during the 6-month 
period (Anova-Manova, p=0.001) (Table 3). Seizure frequency correlated with CSF PB 
concentration in the same manner it did with CSF/S PB concentration ratio, while S PB 
concentration showed no influence on seizure frequency; S PB concentration was within 
therapeutic limits in all patients.  
C3435T polymorphism showed a significant correlation with seizure frequency  (Table 3). 
Patients with CC genotype had a higher seizure frequency than those with CT or TT genotype 
(ANOVA-MANOVA, p<0.001) (Table 3). There were more patients with CT and TT 
genotypes among those with lower number of seizures, and more patients with CC genotype 
among those with higher number of seizures. In the same patients, G2677T polymorphism 
showed no correlation with seizure frequency (p=0.538).  
 
Table 3. Seizure frequency according to CSF/S PB ratio, C3435T and G2677T/A 
polymorphisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Phenobarbital (PB) concentration in cerebrospinal fluid (CSF) AND serum (S), CSF/S PB ratio, and C3435T and G2677T/A polymorphisms in 60 
patients with primary generalized epilepsy with respect to the number of seizures over a 6-month period 
 
No. of seizures Parameter 
0 
(n=10) 
1 
(n=10) 
2 
(n=10) 
3 
(n=14) 
4 
(n=4) 
5 
(n=4) 
6 
(n=2) 
7 
(n=3) 
8 
(n=2) 
9 
(n=1) 
Pa 
PB S (µmol/L) 104.4±9.7 106.4±18.6 93.2±13.2 104.0±34.7 98.8±18.3 108.9±5.6 106.5±19.1 109.7±9.0 93.5±7.8 120.0 0.077 
PB CSF (µmol/L) 65.8±12.4 61.2±15.4 46.9±8.6 51.5±15.8 47.2±10.4 47.2±10.3 43.1±7.4 46.9±4.0 32.7±2.6 33.6 0.001 
CSF/S PB 0.6±0.1 0.6±0.1 0.5±0.1 0.5±0.1 0.5±0.1 0.4±0.1 0.4±0.03 0.4±0.1 0.4±0.01 0.28 0.001 
C3435T polymorphism 
CC (n=16) 0 1 2 3 1 2 2 3 1 1 
CT (n=31) 4 3 8 10 3 2 0 0 1 0 
TT (n=13) 6 6 0 1 0 0 0 0 0 0 
<0.001 
G2677T polymorphism 
GG (n=14) 4 2 2 2 1 1 0 1 1 0 
GT (n=29) 2 2 5 12 2 3 1 2 0 0 
TT (n=17) 4 6 3 0 1 0 1 0 1 1 
0.533 
aANOVA-MANOVA test. 
DISCUSSION 
 
We found that both phenobarbital concentration in the cdrebrospinal fluid and CSF/S PB 
concentration ratio was significantly lower in patients with the CC genotype than in patients 
with CT or TT genotypes of the ABCB1  C3435T polymorphism. The seizure frequency was 
also higher in CC homozygotey in our study.  
A hypothesis of pharmacoresistance currently favored by many authors is decreased drug 
uptake into the brain and its restricted access to the site of action, caused by overexpression of 
the multridrug transporters, such as Pgp, at the blood-brain barrier.5,7,8,14,15,20,21,30-34 As the 
C3435T polymorphism of ABCB1 gene has been associated with the expression and function 
of Pgp in humans, some authors suggest that this polymorphism is associated with the 
response to some AEDs.19,36,37  Our results showed a correlation between C3435T 
polymorphism, CSF/S PB concentration ratio, and frequency of seizures, implying that Pgp 
may play a role in AED pharmacoresistance.  
Results of many previous studies, mainly animal and in vitro, suggested the possible link 
between Pgp and clinical response to AEDs. 7,15,42,29-33 Histopathologic analysis after 
neurosurgical operations in epilepsy patients also suggested the same association.4,6,8,44 
However, connection between C3435T polymorphism and AEDs uptake into the brain has 
never been tested in humans in vivo. The hypothesis is that patients with hyperexpression of 
Pgp at the blood-brain barrier have reduced penetration of AED into the brain, resulting in 
poor therapeuric efficacy. Some studies have demonstrated the interaction of AEDs with 
human Pgp.45-47  Several AEDs have been reported to induce Pgp or inhibit its function.15,22-
27,42 including the recent study by Schuetz et al.48 who showed that phenobarbital induces Pgp. 
However, it is still unclear if some AEDs, including phenobarbiral, could be substrates for 
human Pgp. Crowe and Teoh49 tested a variety of AEDs for their ability to be transported by 
Pgp through Caco-2 monolayers and found only one, acetazolamide, to be a weak substrate of 
human Pgp. On the other hand, Pgp efflux ratios deremined by in vitro high-throughput 
screening tests, where the transport conditions such as pH gradient and concentration are 
fixed, cannot be routinely used to predict a possible limited brain penetration in vivo.50 Our 
results show that C3435T polymorphism of the ABCB1 gene, which encodes Pgp, influences 
the brain uptake of phenobarbital in patients with epilepsy. Whether this finding implies that 
phenobarbital is a human Pgp substrate remains to be confirmed.  
There are also studies that argue against the influence of the ABCB1 gene C3435T 
polymorphism on epilepsy pharmacoresistance.38,39 These studies differed in inclusion criteria 
and involved a large number of patients with symptomatic epilepsy (caused by hippocampal 
sclerosis, cortical dysplasia, stroke, or other reasons). In these patients Pgp hypeexpression 
could have resulted from the action of other local factors in the altered tissue such as a release 
of excitotoxic metabolites during frequent seizures, i.e. irrespective of the ABCB1 gene 
C3435T polymorphism. In addition, these studies also included patients regardless of the type 
of AED therapy they received (monotherapy of polytherapy, substrates of non-substrates of 
Pgp). Thus, inclusion of patients taking valproate could have confounded the results, because 
valproate has not been shown to be a Pgp substrate.21,51,52 Furthermore, competitive inhibition 
in case of AED polytherapy and failure to exclude patients taking other drugs that are 
potential substrates or inhibitors of PGP could also have biased the results of these studies. To 
avoid these possible influences, we included only patients with idiopathic generalized 
epilepsy taking phenobarbital montherapy.  
To the best of our knowledge, the present study is the first to show involvement of ABCB1 
C3435T polymorphism in the brain uptake of an AED in humans in vivo. The seizure 
frequency was found to correlate with CSF/S PB concentration ratio, which fits the 
“decreased drug uptake” theory of pharmacoresistance modulated by Pgp. On the other hand, 
the sample size in our study was small and the results should be interpreted with caution and 
confirmed in a larger number of patients. Although evidence from the literature suggests that 
at least some AEDs are Pgp substrates, the exact influence of C3435T polymorphism on 
different AEDs uptake into the brain, especially in humans, remains to be determined. More 
in vivo human studies including large groups of patients could provide better insight into the 
role of Pgp and ABCB1 polymorphism in epilepsy pharmacoresistance. Also, attention should 
be paid to other factors that may play important roles in the multifactorial phenomenon of 
pharmacoresistance, including  pharmacodynamic and pharmacokinetic mechanisms, 
polytherapy, and other protein transporters at the blood-brain barrier. 
 
 
CONCLUSION 
 
C3435T polymorphism of ABCB1 gene influences the penetration of PB through the blood-
brain barrier. Correlation between C3435T polymorphism of ABCB1 gene, CSF/S PB  
concentration ratio, and seizure frequency also suggests involvement of ABCB1 gene in 
pharmacoresistance of idiopathic primary generalized epilepsies due to reduced drug uptake 
into the brain. Larger in vivo human studies are needed to confirm these results. 
 
 
 
 
 
REFERENCES 
 
1. Sander, J.W.A.S. and Shorvon, S.D. Incidence and prevalence studies in epilepsy and their 
methodological problems: a review.  J Neurol, Neurosurg  Psychiatry 1987;50:829-839. 
 
2. Kosopoulos, I.A., van Merode, T., Kessels FG, de Krom MC, Knottnerus  JA. Systematic 
review and meta-analysis of incidence studies of epilepsy and unprovoked seizures.  
Epilepsia. 2002;43(11):1402-9. 
 
3. Cockerell, O.C., Johnson  AL, Sander  JW, Hart YM,  Shorvon SD. Remission of epilepsy: 
results from the National General Practise Study of Epilepsy.  Lancet 1995;346:140-4. 
 
4. Lazarowski A., Sevlever  G., Taratuto A.,  Massaro  M., Rabinowicz A. Tuberous Sclerosis 
associated with MDR1 gene expression and drug resistant epilepsy.  Pediatric Neurology 
1999;21(4):731-4. 
 
5. Regesta G., Tanganelli  P. Clinical aspects and biological bases of drug-resistant epilepsies.  
Epilepsy Res 1999;34:109-22. 
 
6. Dombrowski SM, Desai  SY, Marroni M., Cucullo  L., Goodrich K., Bingaman W. et al. 
Overexpression of multiple drug resistance genes in endothelial cells from patients with 
refractory epilepsy.  Epilepsia 2001;42:1501-6. 
 
7. Rizzi  M., Caccia  S., Giuso  G., Richichi  C., Gorter  J., Aronica  E. et al. Limbic seizures 
induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistence.  J 
Neurosci 2002;22:5833-9. 
 
8. Sisodiya, S.M., Lin, W.R., Harding, B.N., Squier, M.V., Thom, M. Drug resistance in 
epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy.  
Brain 2003;125(1):22-31. 
  
9. Loscher, W. Animal models of intractable epilepsy.  Prog Neurobiol 1997;53:239-58. 
 
 
10. Ying  W., Dong  Z., Bing W., Huaisu  L., Huixia  C., Qiao  Z. et al. A kindling model of 
pharmacoresistant temporal lobe epilepsy in Sprague-Dawley rats induced by Coriaria 
Lactone and is possible mechanism.  Epilepsia 2003;44:475-88. 
 
11. Bordet, R. Drug-resistant partial epilepsy: pharmacological criteria. Rev Neurol 
2004;160:36-42 
 
12.. Kwan, P., Brodie, M.J. Drug treatment of epilepsy: when does it fail and how to optimize 
its use CNS Spectr 2004;9:110-9. 
 
13. Loscher, W., Schmidt, D. New horizons in the development of antiepileptic drugs: the 
search for new targets.  Epilepsy Res 2004.;60(2-3):77-159. 
 
14. Zimprich, F., Sunder-Plassmann, R., Stogmann, E., Gleiss, A., Dal-Bianco, A.,  
Association af an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy.  
Neurology 2004;63(6):1087-9. 
 
15. Loscher, W. and Potscha, H. Role of multidrug transporters in pharmacoresistance to 
antiepileptic drugs.  J Pharmacol Exp Ther 2002;301(1):7-14. 
 
16. Casetta I, Granieri E, Monetti VC. Early predictors of intractability in childhood epilepsy: 
a community-based case-control study in Copparo, Italy. Acta Neurol Scand 1999;99:329-33. 
 
17. Mac Donald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD.   
Factor predicting prognosis of epilepsy after presentation with seizures.  Ann Neurol 
2000;48:833-41. 
 
18. Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug 
resistance in juvenile myoclonic epilepsy.  J Neurol Neurosurg Psychiatry 2001;70:240-3. 
 
19. Siddiqui A,Kerb R, Weale M, Brinkman U, Smith A,Goldstein D.B, et al. Association of 
multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N  
Engl J Med 2003; 348(15):1442-8. 
 
20. Lombardo AJ, Kuzniecky R, Powers RE, Brown GB. Altered brain sodium channel 
transcript levels in human epilepsy.  Mol Brain Res 1996;35:84-90. 
 
21. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical 
mechanisms.  Epilepsia 2005;46:858-77. 
 
22. Ueda K, Clark DP, Chen CJ, Roninson IB, Goresman MM, Pasan I. The human multidrug 
resisance (mdr1) gene.  cDNA cloning and transcription initiation.  J Biol Chem 
1987;262(2):505-8. 
 23. Chen CJ, Clark D, Ueda K, Pastan I Gottesman MM, Roninsom IB. Genomic organization 
of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 
1990;265(1):506-14. 
 
24. Gottesman MM, Pastan I , Ambudkar SV.  P-glycoproein and multidrug resistance.  Curr 
Opin Genet Dev 1996;6(5):610-7. 
 
25. Burgio DE, Gosland MP, McNamara PJ. Effects of P-glycoprotein modulators on 
etoposide elimination and central nervous system distribution.  J Pharmacol Exp Ther 
1998;287:911-7. 
 
26. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 
Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev 
Pharmacol toxicol 1999;39:361-98. 
 
27. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. 
Pharmacogenomics J 2001;1(1):59-64. 
 
28. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression 
of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. 
J Histochem Cytochem. 1999;38(9):1277-87.  
 
29. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain 
barrier of mice influences the brain penetration and pharmacological activity of many drugs. J 
Clin Invest. 1996;97(11):2517-24. 
 
30.van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, et al. 
Refion-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain 
uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007; 322:141-7. 
 
31.Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter hypothesis of 
drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. 
Neurobiol Dis 2006; 24:202-11. 
 
32. Potschka H, Loscher W. Multidrug resistance-associated proterin is involved in the 
regulation of extracellular levels of phenytoin in the brain.  Neuroreport 2001;12(11):2387-9. 
 
33. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of Phenobarbital, 
lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis 
experiments in rats.  Neurosci Lett 2002;327(3):173-6. 
 
34. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition 
and treatment of brain diseases.  Progress in neurobiology 2005;76:22-76. 
 
35. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A. et al. 
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence 
varations and correlation of one allele with P-glycoproteine expression and activity in vivo.  
Proc Natl Acad Sci USA 2000;97(7):3473-8 
 
36. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 
gene on epilepsy treatment response. Pharmacogenomics. 2005;6(4):411-7. 
 
 
37. Bialecka M. Hnatyszyn G, Bielicka-Cymerman J, Drozdzik M. The effect of MDR1 gene 
polymorphism in the pathogenesis and the treatment of drug-resistant epilepsy. Neurol 
Neurochir Pol. 2005;39(6):476-81. 
 
38. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF. et al. Failure to 
confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. 
Neurology 2004.;63(6):1090-2. 
 
39. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. Lack of 
Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) 
gene and Response to Antiepileptic Drug Treatment. Epilepsia 2005;46(5):643-647. 
 
40.Smith J, Osikowicz G, Abbott AxSYM random and continuous access immunoassay 
system form improved workflow in the clinical laboratory. Clin Chem 1993; 39:2063-9. 
 
41. Miller SA, Dykes DD, Polesky H F. A simple salting out procedure for   extracting DNA 
from human  nucleated cell. Nucl  Acid Res 1988;16 (3):1215. 
 
42. Cascorbi I, Gerloff T, Johne A, Meisel C, et al. Frequency of single nucleotide 
polymorphism in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin 
Pharmacol Ther 2001; 69:169-74. 
 
43. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype related pharmacokinetics 
of digoxin  after oral administration in healthy Japanese subjects. Pharm Res 
2001;18(10):1400-1404. 
 
44. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene 
expression in brain of patients with medically intractable epilepsy. 
Epilepsia. 1995;36(1):1-6. 
 
45. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SMG, Haefeli WE. Interaction of 
antiepileptic  drugs with human P-glycoprotein in vitro.  J Pharmacol Exp Ther 
2003;307(1):262-267. 
 
46. Marchi N, Hallene KL, Kighz KM, Cucullo L, Moddel G, Bingaman W. et al. 
Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. 
BMC Med. 2004;2:37. 
 
47. Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czsech T. et al. A pilot study on brain-
to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and 
MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. 
Epilepsia. 2005;46(10):1613-9. 
 
48. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and 
cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 
Mol Pharamacol 1996;49(2):311-8. 
 49. Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J 
Drug Target. 2006;14(5):291-300. 
 
50. Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein 
transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003;263(1-2):113-
22. 
 
51. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a 
substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in number of in vitro and 
in vivo transport assays. J Pharmacol Exp Ther. 2007;320(1):331-43. 
 
52. Loscher W, Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding 
Cassette Gene Family. NeuroRx 2005;2(1): 86–98. 
 
 
 
 
 
 
 
